PAREXEL International Corp. Stock Rating Lowered by Ned Davis Research (PRXL)
PAREXEL International Corp. (NASDAQ:PRXL) was downgraded by analysts at Ned Davis Research from a “buy” rating to a “neutral” rating in a research report issued to clients and investors on Monday, StockRatingsNetwork reports.
Other equities research analysts have also recently issued reports about the stock. Analysts at Credit Suisse initiated coverage on shares of PAREXEL International Corp. (NASDAQ:PRXL) in a research note to investors on Monday, September 23rd. They set an “outperform” rating on the stock. Separately, analysts at UBS AG initiated coverage on shares of PAREXEL International Corp. (NASDAQ:PRXL) in a research note to investors on Tuesday, September 17th. They set a “buy” rating and a $58.00 price target on the stock. Finally, analysts at Zacks downgraded shares of PAREXEL International Corp. (NASDAQ:PRXL) from an “outperform” rating to a “neutral” rating in a research note to investors on Monday, September 9th. They now have a $55.00 price target on the stock. One research analyst has rated the stock with a sell rating, six have given a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. PAREXEL International Corp. has a consensus rating of “Hold” and an average price target of $45.50.
Shares of PAREXEL International Corp. (NASDAQ:PRXL) traded down 0.08% on Monday, hitting $49.90. 66,879 shares of the company’s stock traded hands. PAREXEL International Corp. has a one year low of $28.45 and a one year high of $53.55. The stock has a 50-day moving average of $48. and a 200-day moving average of $45.70. The company has a market cap of $2.805 billion and a P/E ratio of 31.02.
PAREXEL International Corp. (NASDAQ:PRXL) last announced its earnings results on Wednesday, August 7th. The company reported $0.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.43 by $0.07. The company had revenue of $463.10 million for the quarter, compared to the consensus estimate of $455.23 million. During the same quarter in the previous year, the company posted $0.34 earnings per share. The company’s revenue for the quarter was up 1.2% on a year-over-year basis. On average, analysts predict that PAREXEL International Corp. will post $2.04 earnings per share for the current fiscal year.
PAREXEL International Corporation (NASDAQ:PRXL) is a biopharmaceutical services company, providing a range of expertise in clinical research, medical communications, consulting, and advanced technology products and services to the worldwide pharmaceutical, biotechnology, and medical device industries.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.